JP6942051B2 - 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法 - Google Patents

二量体のコラーゲンハイブリダイゼーションペプチドと使用方法 Download PDF

Info

Publication number
JP6942051B2
JP6942051B2 JP2017540191A JP2017540191A JP6942051B2 JP 6942051 B2 JP6942051 B2 JP 6942051B2 JP 2017540191 A JP2017540191 A JP 2017540191A JP 2017540191 A JP2017540191 A JP 2017540191A JP 6942051 B2 JP6942051 B2 JP 6942051B2
Authority
JP
Japan
Prior art keywords
collagen
peptide
xaa
hybridization
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017540191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508492A5 (enExample
JP2018508492A (ja
Inventor
ジュリアン ケスラー
ジュリアン ケスラー
エス マイケル ユ
エス マイケル ユ
ヤン リ
ヤン リ
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション, ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2018508492A publication Critical patent/JP2018508492A/ja
Publication of JP2018508492A5 publication Critical patent/JP2018508492A5/ja
Priority to JP2021079114A priority Critical patent/JP2021152004A/ja
Application granted granted Critical
Publication of JP6942051B2 publication Critical patent/JP6942051B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
JP2017540191A 2015-01-30 2016-01-29 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法 Active JP6942051B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021079114A JP2021152004A (ja) 2015-01-30 2021-05-07 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562125756P 2015-01-30 2015-01-30
US62/125,756 2015-01-30
PCT/US2016/015816 WO2016123570A1 (en) 2015-01-30 2016-01-29 Dimeric collagen hybridizing peptides and methods of using

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021079114A Division JP2021152004A (ja) 2015-01-30 2021-05-07 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法

Publications (3)

Publication Number Publication Date
JP2018508492A JP2018508492A (ja) 2018-03-29
JP2018508492A5 JP2018508492A5 (enExample) 2019-03-14
JP6942051B2 true JP6942051B2 (ja) 2021-09-29

Family

ID=56544437

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017540191A Active JP6942051B2 (ja) 2015-01-30 2016-01-29 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法
JP2021079114A Pending JP2021152004A (ja) 2015-01-30 2021-05-07 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021079114A Pending JP2021152004A (ja) 2015-01-30 2021-05-07 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法

Country Status (7)

Country Link
US (2) US10953104B2 (enExample)
EP (1) EP3250240A4 (enExample)
JP (2) JP6942051B2 (enExample)
CN (1) CN107530454B (enExample)
AU (1) AU2016211242A1 (enExample)
CA (1) CA2975475A1 (enExample)
WO (1) WO2016123570A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112940A1 (en) * 2015-10-23 2017-04-27 University Of Utah Research Foundation Modified Collagen Hybridizing Peptides And Uses Thereof
WO2018106273A1 (en) * 2016-12-06 2018-06-14 University Of Utah Research Foundation Collagen targeting nanofibers and nanosheets
CN111303249B (zh) * 2020-01-02 2020-12-18 兰州大学 一种特异性检测病变胶原蛋白的探针、制备方法及应用
US12269864B2 (en) 2020-01-03 2025-04-08 Emory University Self-assembling collagen-like polypeptides for applications and uses related thereto
CN111407727B (zh) * 2020-03-26 2021-03-23 浙江大学 哺乳动物雷帕霉素靶蛋白（mTOR）阻断剂在制备治疗钙化性肌腱病药物中的应用
US20220050116A1 (en) * 2020-06-15 2022-02-17 University Of Utah Research Foundation Dimeric collagen hybridizing peptides and methods of use thereof
CN111704663B (zh) * 2020-06-29 2021-09-28 江南大学 一种胶原蛋白水凝胶的制备方法
WO2023034903A1 (en) * 2021-09-01 2023-03-09 3Helix, Inc. Systems and methods for detecting fibrosis
WO2023060218A2 (en) * 2021-10-07 2023-04-13 3Helix, Inc. Biologically active collagen hybridizing peptides
CN116298316B (zh) * 2023-01-18 2024-08-30 中山大学附属第五医院 一种诱导胶原杂交肽保持单链胶原杂交能力的方法及应用
CN116715753B (zh) * 2023-05-11 2024-03-19 中山大学附属第五医院 一种保持单链构象的类肽胶原杂交肽的制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576419A (en) * 1993-06-30 1996-11-19 Regents Of The University Of Minnesota Mild solid-phase synthesis of aligned branched triple-helical peptides
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
MXPA02010787A (es) * 2000-05-03 2003-07-14 Amgen Inc Peptidos modificados como agentes terapeuticos.
US7601694B2 (en) * 2003-02-20 2009-10-13 New York University CLK-peptide and SLK-peptide
WO2007044026A2 (en) * 2004-11-23 2007-04-19 The Johns Hopkins University Compositions comprising modified collagen and uses therefore
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US9758569B2 (en) * 2006-05-26 2017-09-12 Wisconsin Alumni Research Foundation Collagen mimics
CN104113404B (zh) 2008-03-14 2017-09-15 苹果公司 用于无线通信系统的分布式arq
PT2296629E (pt) * 2008-05-09 2014-09-22 Evonik Corp Polímero elastomérico biocompatível e biodegradável
US10426850B2 (en) * 2011-11-22 2019-10-01 The Johns Hopkins University Collagen mimetic peptides for targeting collagen strands for in vitro and in vivo imaging and therapeutic use
JP2015091760A (ja) * 2012-01-23 2015-05-14 学校法人早稲田大学 コラーゲン様ペプチドからなる薬物担体

Also Published As

Publication number Publication date
US11684675B2 (en) 2023-06-27
CN107530454A (zh) 2018-01-02
EP3250240A1 (en) 2017-12-06
US20210322559A1 (en) 2021-10-21
EP3250240A4 (en) 2018-10-10
JP2018508492A (ja) 2018-03-29
WO2016123570A1 (en) 2016-08-04
CN107530454B (zh) 2021-10-26
US10953104B2 (en) 2021-03-23
JP2021152004A (ja) 2021-09-30
AU2016211242A1 (en) 2017-08-17
CA2975475A1 (en) 2016-08-04
US20180000960A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
JP6942051B2 (ja) 二量体のコラーゲンハイブリダイゼーションペプチドと使用方法
US10961317B2 (en) CD20 scFv-ELPs methods and therapeutics
Li et al. Peptide‐based supramolecular hydrogels for delivery of biologics
KR101617790B1 (ko) 치료, 진단과 실험적 혼합물들의 운반을 위한 공학적으로 가변된 나노입자 및 치료용 관련 조성물
KR100484084B1 (ko) 키메라성 폴리펩타이드, 이의 제조 방법 및 용도
CN101500606B (zh) 基于热反应生物聚合物的直接药物送递系统
JP5390621B2 (ja) 二座ペプチドバインダー
JP2008543278A5 (enExample)
AU2003219922A1 (en) Compositions for delivery of therapeutics and other materials, and methods of making and using the same
WO2020192693A1 (zh) 抗Her2抗体药物偶联物药物制剂
WO2018106273A1 (en) Collagen targeting nanofibers and nanosheets
WO2014059384A2 (en) ICAM-1 TARGETING ELPs
JP6984923B2 (ja) アルブミンとの強化された結合親和性を有する医薬構築物
US20240059755A1 (en) Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
CN101544696A (zh) 含色素上皮衍生因子的复合物及其制备方法和应用
JP7766489B2 (ja) 免疫調節特性を有するペプチド
MacAdam et al. Anti-mucus polyclonal antibody production, purification and linkage to the surface of albumin microspheres
TW201809013A (zh) 用於藥物遞送之抗體融合蛋白
US20170112940A1 (en) Modified Collagen Hybridizing Peptides And Uses Thereof
EP4230223A1 (en) Composition
HK40089788A (zh) 纳米脂蛋白-多肽缀合物和组合物、系统以及其使用方法
CN102224162B (zh) 双齿肽结合物
CN120737166A (zh) 一种具备自组装聚性能的蛋白及其制备方法
CN110177574A (zh) 使用适体构建体的药物递送

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210507

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210517

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210615

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210617

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210907

R150 Certificate of patent or registration of utility model

Ref document number: 6942051

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250